Xponance, Inc. Mannkind Corp Transaction History

Xponance, Inc.

$10.1 Billion
Q1 2025

A detailed history of Xponance, Inc. transactions in Mannkind Corp stock. As of the latest transaction made, Xponance, Inc. holds 20,206 shares of MNKD stock, worth $86,683. This represents 0.0% of its overall portfolio holdings.

Number of Shares

20,206

Previous 19,067 5.97%

Holding current value

$86,683

Previous $122,000 17.21%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 30, 2025	BUY	$4.92 - $6.6 $5,603 - $7,517	1,139 Added 5.97%	20,206 $101,000
Q4 2024 Feb 10, 2025	BUY	$5.93 - $7.44 $10,840 - $13,600	1,828 Added 10.6%	19,067 $122,000
Q3 2024 Nov 12, 2024	BUY	$5.01 - $6.7 $3,341 - $4,468	667 Added 4.02%	17,239 $108,000
Q2 2024 Aug 14, 2024	BUY	$4.05 - $5.43 $3,754 - $5,033	927 Added 5.93%	16,572 $86,000
Q1 2024 May 13, 2024	BUY	$3.25 - $5.27 $130 - $210	40 Added 0.26%	15,645 $70,000
Q4 2023 Jan 31, 2024	BUY	$3.34 - $4.29 $1,733 - $2,226	519 Added 3.44%	15,605 $56,000
Q2 2023 Jul 13, 2023	BUY	$3.72 - $4.79 $1,945 - $2,505	523 Added 3.59%	15,086 $61,000
Q4 2022 Jan 23, 2023	BUY	$3.02 - $5.37 $1,407 - $2,502	466 Added 3.31%	14,563 $0
Q3 2022 Oct 24, 2022	BUY	$2.99 - $4.35 $1,629 - $2,370	545 Added 4.02%	14,097 $44,000
Q2 2022 Aug 02, 2022	BUY	$2.67 - $4.77 $4,827 - $8,624	1,808 Added 15.4%	13,552 $52,000
Q1 2022 Apr 20, 2022	BUY	$2.62 - $4.45 $311 - $529	119 Added 1.02%	11,744 $43,000
Q4 2021 Jan 31, 2022	BUY	$4.05 - $5.37 $145 - $193	36 Added 0.31%	11,625 $51,000
Q3 2021 Nov 05, 2021	SELL	$3.89 - $5.48 $7,503 - $10,570	-1,929 Reduced 14.27%	11,589 $50,000
Q2 2021 Aug 12, 2021	BUY	$3.61 - $5.45 $48,799 - $73,673	13,518 New	13,518 $74,000

Others Institutions Holding MNKD

# of Institutions

275

Shares Held

172M

Call Options Held

1.37M

Put Options Held

248K

View Full List

About MANNKIND CORP

Ticker MNKD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 257,338,000
Market Cap $1.1B
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...

More about MNKD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Xponance, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Xponance, Inc. with notifications on news.

Account